Vertex Pharmaceuticals INC / Ma (VRTX) — 10-Q Filings

All 10-Q filings from Vertex Pharmaceuticals INC / Ma. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Vertex Soars on Strong Revenue Growth, Swings to Profit — Nov 4, 2025 Risk: medium
Vertex Pharmaceuticals Inc. reported a significant increase in net income and product revenues for the three and nine months ended September 30, 2025. Product r
Vertex Pharma's Q2 Revenue Jumps 16.7% on Strong Product Sales — Aug 5, 2025 Risk: medium
VERTEX PHARMACEUTICALS INC / MA reported robust financial performance for the second quarter ended June 30, 2025, with total revenue reaching $2.73 billion, a s
Vertex Pharma Q1 2025 Filing: Financial Snapshot — May 6, 2025 Risk: low
Vertex Pharmaceuticals Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's filing details its financial position, i
Vertex Pharmaceuticals Q3 2024 Update — Nov 5, 2024 Risk: low
Vertex Pharmaceuticals Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial statements indicate ongoing ope
Vertex Pharmaceuticals Q2 2024 Update — Aug 2, 2024 Risk: low
Vertex Pharmaceuticals Inc. reported its financial results for the period ending June 30, 2024. The company's filing details its financial position and performa
Vertex Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
VERTEX PHARMACEUTICALS INC / MA (VRTX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Vertex Pharmaceuticals reported financial results for the qu

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX